Ultomiris Europska Unija - hrvatski - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektivni imunosupresivi - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Enspryng Europska Unija - hrvatski - EMA (European Medicines Agency)

enspryng

roche registration gmbh - satralizumab - neuromyelitis optica - imunosupresivi - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Uplizna Europska Unija - hrvatski - EMA (European Medicines Agency)

uplizna

horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - imunosupresivi - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.

Slenyto Europska Unija - hrvatski - EMA (European Medicines Agency)

slenyto

rad neurim pharmaceuticals eec sarl - melatonin - sleep initiation and maintenance disorders; autistic disorder - psycholeptics - slenyto indiciran za liječenje nesanice kod djece i adolescenata u dobi od 2 do 18 s poremećajem autističnog spektra (asd) i / ili smith-magenis sindrom, gdje spavati higijenske mjere su dovoljne.

Cefotaksim-MIP 1 g prašak za otopinu za injekciju/infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

cefotaksim-mip 1 g prašak za otopinu za injekciju/infuziju

mip pharma croatia d.o.o., mihanovićeva 14, zagreb, hrvatska - cefotaksimnatrij - prašak za otopinu za injekciju/infuziju - 1 g - urbroj: 1 bočica sadrži 1 g cefotaksima u obliku cefotaksimnatrija

Cefotaksim-MIP 2 g prašak za otopinu za injekciju/infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

cefotaksim-mip 2 g prašak za otopinu za injekciju/infuziju

mip pharma croatia d.o.o., mihanovićeva 14, zagreb, hrvatska - cefotaksimnatrij - prašak za otopinu za injekciju / infuziju - 2 g - urbroj: 1 bočica sadrži 2 g cefotaksima u obliku cefotaksimnatrija

Zinforo Europska Unija - hrvatski - EMA (European Medicines Agency)

zinforo

pfizer ireland pharmaceuticals - fosamil цефтаролин - community-acquired infections; skin diseases, infectious; pneumonia - antibakterijski lijekovi za sistemsku primjenu, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.

Acipirin 4 g/0,5 g prašak za otopinu za infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

acipirin 4 g/0,5 g prašak za otopinu za infuziju

pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb, hrvatska - piperacilinnatrij tazobaktamnatrij - prašak za otopinu za infuziju - 4,0 g + 0,5 g/bočica - urbroj: jedna bočica sadrži 4,0 g piperacilina u obliku piperacilinnatrija i 0,5 g tazobaktama u obliku tazobaktamnatrija

Axetine 1500 mg prašak za otopinu za injekciju/infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

axetine 1500 mg prašak za otopinu za injekciju/infuziju

medochemie ltd., constatinoupoleos str. 1-10, limassol, cipar - cefuroksimnatrij - prašak za otopinu za injekciju/infuziju - 1500 mg/bočici - urbroj: 1 bočica s praškom za otopinu za injekciju/infuziju sadržava 1500 mg cefuroksima u obliku cefuroksimnatrija

Axetine 750 mg prašak za otopinu za injekciju/infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

axetine 750 mg prašak za otopinu za injekciju/infuziju

medochemie ltd., constatinoupoleos str. 1-10, limassol, cipar - cefuroksimnatrij - prašak za otopinu za injekciju/infuziju - 750 mg/bočici - urbroj: 1 bočica s praškom za otopinu za injekciju/infuziju sadržava 750 mg cefuroksima u obliku cefuroksimnatrija